在与肥胖相关的HFpEF中,塞马格卢提德和NT-proBNP:来自STEP-HFpEF计划的见解
Mark C Petrie1, Barry A Borlaug2, Javed Butler3
1School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
Journal of the American College of Cardiology
|May 31, 2024
概括
在患有与肥胖相关的心力衰竭患者中,塞马格卢提德显著降低了NT-proBNP水平,并保留了喷射分数 (HFpEF). 那些基线NT-proBNP较高的人经历了更大的症状改善,尽管体重减轻类似.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 与肥胖相关的心力衰竭与保存的喷射分数 (HFpEF) 提出了复杂的挑战.
- 作为GLP-1受体激动剂的塞马格卢提德 (Semaglutide) 在改善HFpEF患者的健康状况和减肥方面表现有前途.
- 在HFpEF中semaglutide的好处背后的精确机制仍在调查中.
研究的目的:
- 评估2.4毫克塞马格卢对与肥胖相关的HFpEF患者的N-终端B型亲尿素 (NT-proBNP) 水平的影响.
- 根据基线NT-proBNP水平来比较治疗反应.
主要方法:
- 从两个随机,双盲,安慰剂对照试验 (STEP-HFpEF和STEP-HFpEF DM) 的汇总数据的预规定的二次分析.
- 参与者有与肥胖相关的HFpEF.
- 关键结果包括NT-proBNP的变化,堪萨斯城心肌病问卷临床总结得分和52周的体重,由基线NT-proBNP三位体和连续变量分析.
主要成果:
- 与安慰剂相比,塞马格卢提德显著降低了NT-proBNP水平 (估计治疗比:0.82;P = 0.0002).
- 在基线NT-proBNP水平较高的患者中,健康状况的改善更为明显 (P相互作用=0.004).
- 在所有基线NT-proBNP水平 (P相互作用=0.21) 上,体重减轻一致.
结论:
- 在患有与肥胖相关的HFpEF的患者中,塞马格卢提德有效降低NT-proBNP.
- 患有较高基线NT-proBNP的患者经历了更大的症状缓解和功能性改善与semaglutide,独立于跨组观察到的类似体重减轻.
相关概念视频
01:24Glucagon-like Receptor Agonists
316
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:23Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181